JP6185650B2 - ５−ｈｔ４受容体アゴニストとしての５−アミノ−キノリン−８−カルボキサミド誘導体 - Google Patents

５−ｈｔ４受容体アゴニストとしての５−アミノ−キノリン−８−カルボキサミド誘導体 Download PDF

Info

Publication number
JP6185650B2
JP6185650B2 JP2016504852A JP2016504852A JP6185650B2 JP 6185650 B2 JP6185650 B2 JP 6185650B2 JP 2016504852 A JP2016504852 A JP 2016504852A JP 2016504852 A JP2016504852 A JP 2016504852A JP 6185650 B2 JP6185650 B2 JP 6185650B2
Authority
JP
Japan
Prior art keywords
quinoline
carboxamide
amino
methyl
piperidinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016504852A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016516089A (ja
Inventor
ラマクリシュナ・ニロギ
アニル・カーバリ・シンデ
ヴェンカテスワール・ジャスティ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suven Life Sciences Ltd
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of JP2016516089A publication Critical patent/JP2016516089A/ja
Application granted granted Critical
Publication of JP6185650B2 publication Critical patent/JP6185650B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
JP2016504852A 2013-03-20 2013-10-18 ５−ｈｔ４受容体アゴニストとしての５−アミノ−キノリン−８−カルボキサミド誘導体 Expired - Fee Related JP6185650B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1199/CHE/2013 2013-03-20
PCT/IN2013/000639 WO2014147636A1 (en) 2013-03-20 2013-10-18 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists
IN1199CH2013 IN2013CH01199A (cg-RX-API-DMAC7.html) 2013-03-20 2013-10-18

Publications (2)

Publication Number Publication Date
JP2016516089A JP2016516089A (ja) 2016-06-02
JP6185650B2 true JP6185650B2 (ja) 2017-08-23

Family

ID=54325095

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016504852A Expired - Fee Related JP6185650B2 (ja) 2013-03-20 2013-10-18 ５−ｈｔ４受容体アゴニストとしての５−アミノ−キノリン−８−カルボキサミド誘導体

Country Status (18)

Country Link
US (1) US9790211B2 (cg-RX-API-DMAC7.html)
EP (1) EP2976337B1 (cg-RX-API-DMAC7.html)
JP (1) JP6185650B2 (cg-RX-API-DMAC7.html)
KR (1) KR101815307B1 (cg-RX-API-DMAC7.html)
CN (1) CN105164119B (cg-RX-API-DMAC7.html)
AP (1) AP2015008742A0 (cg-RX-API-DMAC7.html)
AU (1) AU2013382944B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015024060A2 (cg-RX-API-DMAC7.html)
CA (1) CA2907620C (cg-RX-API-DMAC7.html)
DK (1) DK2976337T3 (cg-RX-API-DMAC7.html)
EA (1) EA029365B1 (cg-RX-API-DMAC7.html)
ES (1) ES2674993T3 (cg-RX-API-DMAC7.html)
IN (1) IN2013CH01199A (cg-RX-API-DMAC7.html)
MX (1) MX364929B (cg-RX-API-DMAC7.html)
NZ (1) NZ712369A (cg-RX-API-DMAC7.html)
SG (1) SG11201507763RA (cg-RX-API-DMAC7.html)
WO (1) WO2014147636A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201506804B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3265459T (pt) * 2015-02-13 2019-07-17 Suven Life Sciences Ltd Compostos amidos como agonistas do recetor 5-ht4
CN109444301A (zh) * 2018-12-18 2019-03-08 江苏省中医院 一种测定血浆中普芦卡必利浓度的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08502273A (ja) * 1992-10-13 1996-03-12 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５−ｈｔ▲下４▼レセプターアンタゴニスト用複素環式エステルまたはアミド
AU680453B2 (en) 1992-11-05 1997-07-31 Smithkline Beecham Plc Piperidine derivatives as 5-HT4 receptor antagonists
FR2756564B1 (fr) * 1996-12-04 2004-05-14 Synthelabo Derives d'acide quinoleine-8-carboxylique, leur preparation et leur application en therapeutique
AU2001225664A1 (en) * 2000-06-15 2001-12-24 Respiratorius Ab 5-ht3 receptor antagonists for treatment of disorders involving airway constriction
PT1638959E (pt) 2003-06-19 2007-12-12 Janssen Pharmaceutica Nv 4-(aminometil)piperidinobenzamidas antagonistas de 5ht4
ES2338882T3 (es) 2003-11-24 2010-05-13 Pfizer, Inc. Compuestos de acido quinolona-carboxilico que tienen actividad agonista del receptor 5-ht4.
EP1701951B1 (en) * 2003-12-23 2010-02-10 Serodus AS Modulators of peripheral 5-ht receptors
WO2005092882A1 (en) * 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
WO2006090224A1 (en) 2005-02-25 2006-08-31 Pfizer Japan Inc. Benzisoxazole derivatives
DE602006010563D1 (de) 2005-07-22 2009-12-31 Pfizer Indazolcarbonsäureamidderivate als agonisten des 5ht4-rezeptors
GB0525661D0 (en) * 2005-12-16 2006-01-25 Glaxo Group Ltd Novel compounds
BR112012020060B8 (pt) * 2010-02-12 2021-05-25 Askat Inc uso de n-((1-((4-hidroxitetrahidro-2h-piran-4-il)metil)piperidin-4-il)metil)-3-isopropil-2-oxo-2,3-dihidro-1h-benzo[d]imidazol-1-carboxamida para tratar doença de alzheimer e demência
JP2013519722A (ja) 2010-02-16 2013-05-30 ファイザー・インク （ｒ）−４−（（４−（（４−（テトラヒドロフラン−３−イルオキシ）ベンゾ［ｄ］イソオキサゾール−３−イルオキシ）メチル）ピペリジン−１−イル）メチル）テトラヒドロ−２ｈ−ピラン−４−オール、５−ｈｔ４受容体の部分アゴニスト

Also Published As

Publication number Publication date
WO2014147636A8 (en) 2014-12-04
US9790211B2 (en) 2017-10-17
CA2907620A1 (en) 2014-09-25
SG11201507763RA (en) 2015-10-29
AP2015008742A0 (en) 2015-09-30
EP2976337B1 (en) 2018-05-02
AU2013382944B2 (en) 2016-08-04
CA2907620C (en) 2018-03-13
NZ712369A (en) 2016-11-25
WO2014147636A1 (en) 2014-09-25
US20160280694A1 (en) 2016-09-29
EA201591844A1 (ru) 2016-08-31
HK1217483A1 (zh) 2017-01-13
MX2015012350A (es) 2016-05-09
CN105164119B (zh) 2017-12-08
ES2674993T3 (es) 2018-07-05
KR101815307B1 (ko) 2018-01-04
AU2013382944A1 (en) 2015-10-08
IN2013CH01199A (cg-RX-API-DMAC7.html) 2015-08-14
EA029365B1 (ru) 2018-03-30
BR112015024060A2 (pt) 2017-07-18
DK2976337T3 (en) 2018-07-16
MX364929B (es) 2019-05-14
JP2016516089A (ja) 2016-06-02
CN105164119A (zh) 2015-12-16
ZA201506804B (en) 2016-07-27
KR20160004274A (ko) 2016-01-12
EP2976337A1 (en) 2016-01-27

Similar Documents

Publication Publication Date Title
JP6487564B2 (ja) ５−ｈｔ４受容体アゴニストとしてのアミド化合物
JP6096370B2 (ja) 置換トリアゾロピリジンとその使用方法
JP2021527112A (ja) ニューロキニン−１受容体アンタゴニストとしての化合物およびその使用
JP2020502248A (ja) Ｒｈｏキナーゼ阻害剤ＢＡ‐１０４９（Ｒ）及びその活性代謝物
JP5540099B2 (ja) ５−ｈｔ４受容体リガンドとしての１，２−ジヒドロ−２−オキソキノリン化合物
RU2469033C2 (ru) СОЕДИНЕНИЯ ДИБЕНЗО[b,f][1,4]ОКСАЗАПИНА
JP6185650B2 (ja) ５−ｈｔ４受容体アゴニストとしての５−アミノ−キノリン−８−カルボキサミド誘導体
JP2023085342A (ja) 置換（４’－ヒドロキシフェニル）シクロアルカンおよび（４’－ヒドロキシフェニル）シクロアルケン化合物ならびに記憶固定を向上させるためのエストロゲン受容体βアイソフォームの選択的アゴニストとしてのそれらの使用方法
JP2019528267A (ja) Ｇａｂａ（ａ）受容体モジュレーター、及び、喘息における気道過敏及び炎症を抑制するための方法
TW202116755A (zh) 可用為幾丁質酶抑制劑的經取代的胺基三唑
JP2015529254A (ja) 喘息における気道の過敏症及び炎症を制御するための新規なｇａｂａａアゴニスト及び使用方法
JP6055784B2 (ja) パロキセチン誘導体
TW200836732A (en) Novel compounds
CN116554144A (zh) 一种sj系列芳基苯胺类化合物及其制备方法与医药用途
JP2025540641A (ja) 選択的β２アドレナリン受容体アンタゴニスト
HK1217483B (en) 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists
HK1241363B (zh) 作为5-ht4受体激动剂的酰胺化合物
HK1173140B (en) 1,2-dihydro-2-oxoquinoline compounds a 5-ht4 receptor ligands
HK1241363A1 (en) Amide compounds as 5-ht4 receptor agonists
HK1136289A (en) Dibenzo[b,f][1,4]oxazapine compounds

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20151120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170524

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170703

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170727

R150 Certificate of patent or registration of utility model

Ref document number: 6185650

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees